Thrombosis
Conference Coverage
Antiplatelet drugs comparable in patients with AMI
Photo courtesy of AstraZeneca ROME—The antiplatelet drugs prasugrel and ticagrelor produce similar early results in patients with acute...
Conference Coverage
Antidote to factor Xa inhibitors exhibits efficacy in patients with major bleeding
ROME—Preliminary results from the ANNEXA-4 study suggest that andexanet alfa, an investigational antidote to factor Xa inhibitors, can be...
Conference Coverage
Antiplatelet monitoring doesn’t benefit high-risk patient group
Photo courtesy of NIH ROME—Results of the ANTARCTIC trial suggest that monitoring platelet function to individualize antiplatelet therapy does...
Conference Coverage
Rule identifies women at low risk of VTE recurrence
of women in a family ROME—According to researchers, a clinical decision rule can identify women who, after their first unprovoked venous...
Conference Coverage
Two NOACs pose lower risk of ICH in real-world study
Photo courtesy of Pfizer and Bristol-Myers Squibb ROME—Novel oral anticoagulants (NOACs) are as effective as warfarin for preventing stroke but...
Conference Coverage
Shorter DAPT appears safe for pts with type of DES
Patients in this study, known as NIPPON, had the Nobori bioabsorbable abluminal-coated stent and received 6 months or 18 months of DAPT, which...
Conference Coverage
VIDEO: NOACs cut intracranial bleeds in real-world atrial fib patients
News
Reversible FXIa inhibitor may reduce bleeding risk
Photo by Sakurai Midori Researchers say they have developed an antibody that inhibits factor XIa (FXIa) without increasing the risk of bleeding,...
News
Nanoparticles speed blood clotting in multiple models
form clots in injured liver Image courtesy of Erin Lavik PHILADELPHIA—Researchers say they have developed nanoparticles that can congregate at...
News
VTE linked to permanent work-related disability
Image by Andre E.X.
News
FDA rejects antidote to factor Xa inhibitors
Photo courtesy of Pfizer and Bristol-Myers Squibb The US Food and Drug Administration (FDA) has issued a complete response letter regarding the...